SCHEMBL1315432

SCHEMBL1315432

CC(C)(C)OC(=O)c1ccc(-c2ccccc2)cc1NC(=O)c1cncc(Br)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.60
HSD17B10 Q99714 2/20 0.57
POLB P06746 1/20 0.57
TSHR P16473 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
ALDH1A1 P00352 4/20 0.55
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
SMN1; SMN2 Q16637 4/20 0.47
GAA P10253 2/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
HDAC1 Q13547 3/20 0.45
HPGD P15428 2/20 0.44
KDM4E B2RXH2 2/20 0.44
KDR P35968 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1317609 0.91 HDAC1 (0.47) MAPK1HSD17B10POLBTSHRNPSR1
SCHEMBL1317220 0.88 MAPK1 (0.52) MAPK1HSD17B10POLBTSHRNPSR1
SCHEMBL12118133 0.87 CHRNA7 (0.48) MAPK1HSD17B10POLBTSHRNPSR1
SCHEMBL12118191 0.87 HDAC1 (0.49) MAPK1HSD17B10POLBTSHRNPSR1
SCHEMBL12118095 0.86 HDAC1 (0.46) MAPK1HSD17B10POLBTSHRNPSR1
SCHEMBL12118144 0.86 HDAC1 (0.53) HDAC1KDM4EHDAC3HDAC2
SCHEMBL12118101 0.85 HDAC2 (0.48) MAPK1HSD17B10POLBTSHRNPSR1
SCHEMBL2270475 0.85 HDAC1 (0.43) MAPK1HSD17B10POLBTSHRNPSR1
SCHEMBL12121805 0.85 ALDH1A1 (0.75) MAPK1HSD17B10POLBTSHRNPSR1
SCHEMBL12118098 0.84 CTSA (0.44) MAPK1HDAC1MAPTHDAC3HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492582-B2 N-acyl anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2013-07-23 US disclosed
US-8492582-B2 N-acyl anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2013-07-23 US disclosed
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2011-11-10 US disclosed
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2011-11-10 US disclosed
EP-2385036-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF Toyama Chemical Co., Ltd. (JP) 2011-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF COL14A1, COL2A1, COL1A1 MAPK1 1161/4885HSD17B10 536/4885POLB 4339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.